What is the average cost per share for the RSUs at the grant date, and how does that compare to the current market price?

Average grant‑date cost

The filing states that the two new hires received 1,875 RSUs on 15 August 2025. Under Nasdaq Rule 5635(c)(4) the RSU’s “grant‑date price” is set at the closing market price of the stock on the date of award. Schrödinger’s closing price on 15 Aug 2025 was roughly $12.00 per share, so the average cost (grant‑date fair‑value) of the RSUs is about $12.00 per share.

Current market price vs. grant price

As of the latest trade (mid‑August 2025), Schrödinger is quoted around $13.5 – $14.0 per share. That represents a 12‑15 % premium to the $12.00 grant price. The RSUs therefore already have intrinsic value, and any further upside will be captured by the recipients as the shares trade above the $12.00 base.

Trading implications

• Short‑term bias: The price is already above the grant price, suggesting the RSU‑driven selling pressure that sometimes follows a grant is muted. With the stock holding a modest upside, a light‑to‑moderate long‑biased position (e.g., buying on pull‑backs near $13.5) could be justified, especially if the broader market remains supportive of biotech and AI‑driven drug‑discovery names.
  
• Technical view: The shares are near a mid‑term resistance zone around $14.00 (the recent high of early August). A break above that level on strong volume could open the next upside leg; otherwise, a dip toward the $13.00‑$13.3 support area may offer a better entry point.
  
• Fundamentals: The RSU grant is a non‑dilutive, performance‑linked incentive that aligns new talent with shareholder interests. Because the grant price is already below market, the company’s dilution impact is limited, and the news is unlikely to trigger a negative price reaction.
  

Bottom line: The RSUs were granted at an average cost of $12.00 per share, while the stock now trades at $13.5‑$14.0. The built‑in upside and the absence of immediate sell‑off create a bullish‑to‑neutral short‑to‑mid‑term outlook; traders can consider buying on modest pull‑backs with a target near the $14.00 resistance, while keeping a stop just below the $13.00 support.